BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05357989 (Buntanetap in Parkinson's Disease): BVCT ex-ante prediction vs. reported outcome

On 24 Mar 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 2 Jul 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05357989
Drug Name
Buntanetap
Drug MoA
neurotoxic protein synthesis inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Parkinson's Disease
Human Patients
523
Sponsor
Annovis Bio
Phase
Phase 3

Prediction of , index 934

Prospective Prediction
Prediction Index
934
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
FAILURE (statistically maybe significant yet very weak clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
100 days in advance
Readout Data Interpretation
primary efficacy endpoint not met in presentation rather than press release (x.com/adamfeuerstein/status/1808471091066581487)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease
Phase
Phase 3
Status
Completed
Enrollment
523
Lead sponsor
Annovis Bio Inc.
Conditions
Parkinson's Disease, Idiopathic
Interventions
DRUG: buntanetap/posiphen; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2022-08-03
Primary completion
2023-12-04
Completion
2023-12-04
Results first posted
2025-03-03
Primary outcomes
  • Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state) (Baseline and 6 months visits)

NCT05357989 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials